左乙拉西坦联合氟哌啶醇治疗小儿自闭症临床研究  

Clinical Study of Levetiracetam Combined with Haloperidol in the Treatment of Children with Autism

作　　者：倪金凤[1] 张洁[1] 党媛媛 刘国玉 NI Jinfeng;ZHANG Jie;DANG Yuanyuan;LIU Guoyu(Tangshan Maternal and Child Health Hospital,Tangshan,Hebei,China 063000)

机构地区：[1]河北省唐山市妇幼保健院,河北唐山063000

出　　处：《中国药业》2022年第18期97-99,共3页China Pharmaceuticals

基　　金：河北省医学科学研究重点课题[20171324]。

摘　　要：目的探讨左乙拉西坦联合氟哌啶醇治疗小儿自闭症的临床疗效。方法选取医院2018年10月至2020年10月收治的自闭症患儿108例,采用随机数字表法分为观察组和对照组,各54例。两组患儿均予氟哌啶醇片口服,观察组加服左乙拉西坦片。两组均连续治疗4周。结果观察组总有效率为90.74%,显著高于对照组的72.22%(P<0.05)。观察组患儿治疗后的自闭症儿童发展评定量表评分、自闭症行为检查量表评分均显著低于对照组;脑源性神经营养因子(BDNF)及B淋巴细胞瘤-2(Bcl-2)蛋白表达水平均显著高于对照组;大体功能评定量表评分、认知功能筛查量表评分均显著高于对照组,社会功能缺陷筛选表评分显著低于对照组(P<0.05)。观察组与对照组不良反应发生率相当(14.81%比9.26%,P>0.05)。结论左乙拉西坦联合氟哌啶醇治疗小儿自闭症,能改善患儿的症状评分、社会行为能力及BDNF、Bcl-2蛋白的表达水平。Objective To investigate the clinical efficacy of levetiracetam combined with haloperidol in the treatment of children with autism.Methods A total of 108 children with autism admitted to the hospital from October 2018 to October 2020 were selected and randomly divided into the observation group and the control group according to the random number table method,with 54 cases in each group.The children in the two groups were given Haloperidol Tablets,on this basis,the children in the observation group were given Levetiracetam Tablets.Both groups were treated continuously for four weeks.Results The total effective rate in the observation group was 90.74%,which was significantly higher than 72.22% in the control group(P<0.05).After treatment,the scores of the Children Autism Rating Scale(CARS)and the Autism Behavior Checklist(ABC)in the observation group were significantly lower than those in the control group,the levels of brain-derived neurotrophic factor(BNDF)and B lymphocyte tumor-2(Bcl-2)protein in the observation group were significantly higher than those in the control group,the scores of the Global Assessment Function(GAF)and the Cognitive Abilities Screening Instrument(CASI)in the observation group were significantly higher than those in the control group,while the scores of the Social Disability Screening Schedule(SDSS)in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse drug reactions in the observation group was similar to that in the control group(14.81%vs.9.26%,P>0.05).Conclusion Levetiracetam combined with haloperidol in the treatment of children with autism can improve the symptom score,social behavior ability,and the expression levels of BDNF and Bcl-2 protein.

关 键 词：小儿自闭症 左乙拉西坦 氟哌啶醇 脑源性神经营养因子 B淋巴细胞瘤-2 

分 类 号：R969.4[医药卫生—药理学] R971.6[医药卫生—药学]